Study to Evaluate Maximum Tolerated Dose of Oral CB-03-10 With Dose Expansion Phase, in Advanced Solid Tumors

UNKNOWN

EARLY_PHASE1Ages 18+InterventionalTreatment

Cosmo Technologies Ltd

~90 participants

Updated 2024-02-07 on ClinicalTrials.gov

What's tested:CB-03-10

At a glance

Recruiting sites

6 of 6 listed sites are recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Determine the maximum tolerated dose

Measured over 29 days

+1 more outcome measured

Advanced Refractory Solid Tumors

Subjects Considered Likely to Respond to CB-03-10

NCT03863145

This study runs at 6 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

Barbara Ann Karmanos Cancer Institute
Michigan Center, Michiganno site contact published
Recruiting
Gabrail Cancer Center
Ohio City, Ohiono site contact published
Recruiting
Tranquil Clinical Research
Texas City, Texasno site contact published
Recruiting
University of California Irvine Health Chao Family Comprehensive Cancer Center
California City, Californiano site contact published
Recruiting
University of Colorado Cancer Center
Colorado Springs, Coloradono site contact published
Recruiting
Yale Cancer Center
New Haven, Connecticutno site contact published
Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Cristina Banyai

Opens a ready-to-send draft in your own email app — review before sending.

Determine the maximum tolerated dose29 days
Determine the maximum tolerated dose (MTD) of CB-03-10 in subjects with advanced solid tumors
Determine the dose-limiting toxicity28 days
Determine the dose-limiting toxicity (DLT) of CB-03-10 in subjects with advanced solid tumors